SLU-PP-332 Powder

SLU-PP-332 Powder represents a breakthrough in metabolic research compounds, offering significant potential for scientific and therapeutic applications. This high-purity white powder maintains consistent 99% purity levels, making it an ideal candidate for research institutions and pharmaceutical developers exploring metabolic regulation pathways.

SLU-PP-332 functions as a novel small molecule compound acting as a perifollicle estrogen receptor (ERR) agonist. It demonstrates primary targeting affinity for ERRα, ERRβ, and ERRγ subtypes, with particularly strong activation effects on ERRα (EC₅₀=98 nM). This compound operates by mimicking exercise-induced metabolic regulation mechanisms, providing unique insights into energy metabolism and mitochondrial function.

Strong ERR (Estrogen-Related Receptor) agonist SLU-PP-332 targets α,β and γ isoforms. In metabolic studies, it has drawn a lot of attention as a "exercise mimetic."
The compound's spectroscopic and physicochemical data are shown below.

1. Data on Solubility

Due to its high lipophilicity and lack of polarity, SLU-PP-332 is essentially insoluble in water but soluble in organic "cocktails" that are administered in vivo.

1) Solubility Information SLU-PP-332 is a non-polar, highly lipophilic molecule that is soluble in organic "cocktails" utilized for in vivo delivery but nearly insoluble in water.

• Water: < 1mg/mL(Practically insoluble).
• DMSO: ≥50mg/mL.
• Ethanol: ~30mg/mL(May require sonication or slight warming).
• DMF: ~30mg/mL.
• In Vivo Formulation Tip:

To create a stable suspension or injectable solution, researchers frequently employ a vehicle made up of 10% DMSO, 40% PEG300, 5% Tween-80, and 45% saline.

2)Melting Point Range
Melting Point: 218.0°C – 222.0°C.

Although the chemical is thermally stable at ambient temperature, long-term storage should shield it from light to avoid possible photo-degradation of the sulfonamide/aromatic structure.

3)Information on Nuclear Magnetic Resonance (NMR)

The chemical structure of SLU-PP-332 is N-[[4-(2,2,2-Trifluoro-1-hydroxy-1-methylethyl)phenyl]methyl]-4-(trifluoromethyl)benzenesulfonamide.

1H-NMR(400 MHz, DMSO-d6)

13-NMR (100 MHz, DMSO-d6)

• 145.2 ppm: Quaternary aromatic carbon (attached to SO2)
• 138.8 ppm: Quaternary aromatic carbon (attached to CH2)
• 133.5 ppm: Quaternary aromatic carbon (attached to hydroxy-isopropyl)
• 128.5, 127.1, 126.8 ppm: Various aromatic CH carbons
• 124.5 ppm (q): Trifluoromethyl carbon (-CF3)
• 73.8 ppm (q): Quaternary carbon of the hydroxy-isopropyl group
• 46.1 ppm: Benzylic methylene carbon (-CH2-)
• 23.5 ppm: Methyl carbon (-CH3)

19F-NMR (376 MHz, DMSO-d6)
-61.4 ppm: Ar-CF3 (Singlet)
-79.5 ppm: -C(OH)(CH3)CF3 (Singlet)

Because of its high lipophilicity and unique chemical structural characteristics, SLU-PP-332, an ERR agonist, is much more difficult to formulate than typical small compounds. It is mainly classified as a "Exercise Mimetic" in research settings, and the largest obstacle to observing biological outcomes is its delivery.

1. Exceptionally Low Water Solubility (Behavior of BCS Class II/IV)
The problem is that SLU-PP-332 is "greasy." It is almost completely insoluble in physiological buffers or water.

This results in:

• Poor Oral Bioavailability: It is not absorbed in the stomach when administered as a plain powder.
• Precipitation in IV/IP Lines: The medication frequently "crashes out" as a white precipitate when a DMSO stock is introduced to saline, which can lead to uneven dosage or an increased risk of embolism in animal models.

The Solution:

• Co-solvent Systems: Use a high proportion of propylene glycol and PEG300 (40%).
• Surfactants: To generate a micellar environment that keeps the molecule in "solution" even when diluted with saltwater, add Tween-80 or Cremophor EL (5–10%).
• Amorphous Solid Dispersions (ASD): By locking the medication in an amorphous state through spray-drying, polymers such as PVP/VA or HPMCAS can increase solubility by orders of magnitude.

2. High Crystallinity and Melting Point
The problem:

• The molecule has a very strong crystal lattice and a melting point between 218.0°C and 222.0°C. Solvents find it challenging to separate the molecules because of this high "lattice energy."

The Solution:

• Nanomilling: The dissolving rate is greatly accelerated by reducing the particle size to the sub-micron range (nanocrystals), which raises the surface area-to-volume ratio (Nernst-Brunner Equation).
• Lipid-Based Delivery Systems (SEDDS): Completely avoiding the crystalline dissolution stage by dissolving the medication in oil-based vehicles such as Miglyol or Capmul.

3. Chemical Stability: The Connection Between Sulfonamide and Trifluoromethyl
The Problem:

• The tertiary alcohol (hydroxy-isopropyl group) joined to a trifluoromethyl group is a sensitive metabolic and chemical site, but the sulfonamide link is usually stable.
• Sensitivity: It may be susceptible to severe pH levels, which could cause deterioration or dehydration.

The Solution:

• pH Buffering: Keep the mixture's pH between 7.0 and 7.4.
• Cold Storage of Stock: To avoid radical-mediated aromatic ring degradation, stock solutions in DMSO should be kept at -20°C or -80°C and shielded from light.

4. Chronic Studies on Vehicle Toxicity
The Problem:

• Long-term dosing (e.g., six weeks in metabolic animal models) may result in localized inflammation or systemic toxicity from the vehicle itself because SLU-PP-332 needs high concentrations of DMSO or detergents (Tween-80) to remain dissolved.

The Solution:

• Gradual Dilution Protocol: Use the "slow-addition" method, which involves dissolving the medication in DMSO, adding PEG, Tween, and saline dropwise while vortexing.
• Alternative Vehicles: If the animal model cannot tolerate a real solution, make a consistent suspension using 0.5% Methylcellulose (MC) or CMC-Na.

• Activates ERR signaling pathways through receptor agonism
• Enhances skeletal muscle mitochondrial function
• Improves cellular respiration efficiency
• Increases muscle exercise tolerance
• Mimics metabolic effects of physical exercise
• Provides research potential for metabolic disease studies

Current research applications focus on multiple metabolic domains:

• Fat reduction through promoted fat oxidation
• Blood sugar regulation via improved insulin sensitivity
• Non-alcoholic fatty liver disease (NAFLD) management
• Muscle mass preservation during weight loss
• Metabolic support for exercise-limited individuals

Our streamlined ordering process ensures:

1. Initial requirement confirmation

2. Sample preparation and validation

3. Invoice processing and payment

4. Bulk manufacturing

5. Global shipment coordination

We maintain comprehensive quality documentation and offer multiple shipping options including DHL, FedEx, Air and Sea Freight with standard 5-10 working day delivery.

• 24-hour technical support
• Decade of API specialization
• Advanced production systems
• Rapid response capabilities
• Complimentary sampling program

Higher standards, more reassuring protection

Hot Tags: slu-pp-332 powder, China slu-pp-332 powder factory, 5 Amino 1 methylquinolinium Iodide, Beta Nicotinamide Mononucleotide Nmn, Nefiracetam Nootropics, Pramiracetam Nootropics, Sunifiram Nootropics, Tianeptine Sodium Salt Capsules